ASH was not on target to be a significant catalyst IMO. It was likely to continue the momentum of positive news, but nothing earth shattering was expected. It did end up key to running over $80 to an ATH.
Ort, look at the days you have posted on this board in recent few months. Almost 100% on negative days, screaming the sky is falling and that company is only worth a PPS in the 60s.
What is unique and what you ignore, as Rob Cos continues to articulate, is that ASH is not the only data/news flow in the very near term. For many it is, but NOT for CELG.
Apremilast will soon report Ps Phase 3 data and additional PsA mono-treatment data. Pom approval announcement could be any upcoming Friday before the PDUFA data [only 9 Friday's left per my count], January we get detailed PC data presented. Q1 we get MM-020 data. Revlimid likely to see further geo expansion in the coming weeks and months. Early 2013, PsA apremilast will be filed in the US and later in 2013 pom will be likely approved in EMA. 2013 PC/Abraxane will be filed in the US.
Keep shorting ort...
I'll keep using your negative posts as buy indicators.